Literature DB >> 9580755

Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements.

D C Wilson1, L Ellis, J Zielenski, M Corey, W F Ip, L C Tsui, E Tullis, M R Knowles, P R Durie.   

Abstract

The diagnosis of cystic fibrosis (CF) is not always certain, despite extensive clinical evaluation, multiple sweat chloride tests, and genotype analysis. We hypothesized that nasal transepithelial potential difference measurements have a useful role in this situation. In 11 patients without an established diagnosis of CF, results of simultaneous nasal potential difference (PD) and sweat chloride measurements were compared with those from control subjects, obligate CF heterozygotes, and patients with a confirmed diagnosis of CF. Two patients conformed to the PD profile for CF patients, whereas nine had values corresponding to those of the healthy control subjects. Subsequently the 5-thymidine (IVS8-5T) CF gene variant was identified in the two patients with abnormal PD measurements.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580755     DOI: 10.1016/s0022-3476(98)70345-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

Review 1.  Atypical cystic fibrosis--diagnostic and management dilemmas.

Authors:  Colin Wallis
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 2.  Patterns of GI disease in adulthood associated with mutations in the CFTR gene.

Authors:  Michael Wilschanski; Peter R Durie
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

3.  The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era.

Authors:  Avantika Mishra; Ronda Greaves; John Massie
Journal:  Clin Biochem Rev       Date:  2005-11

Review 4.  Diagnosis of cystic fibrosis: Indian perspective.

Authors:  S K Kabra; G J Connett; C J Rolles
Journal:  Indian J Pediatr       Date:  1999 Nov-Dec       Impact factor: 1.967

5.  Phenotypic and genetic characterization of patients with features of "nonclassic" forms of cystic fibrosis.

Authors:  Joshua D Groman; Barbara Karczeski; Molly Sheridan; Terry E Robinson; M Daniele Fallin; Garry R Cutting
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

Review 6.  Patterns of gastrointestinal disease associated with mutations of CFTR.

Authors:  Michael Wilschanski
Journal:  Curr Gastroenterol Rep       Date:  2008-06

7.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

8.  Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies.

Authors:  Viral S Shah; Sarah Ernst; Xiao Xiao Tang; Philip H Karp; Connor P Parker; Lynda S Ostedgaard; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

9.  Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer.

Authors:  Christopher S Rogers; Yanhong Hao; Tatiana Rokhlina; Melissa Samuel; David A Stoltz; Yuhong Li; Elena Petroff; Daniel W Vermeer; Amanda C Kabel; Ziying Yan; Lee Spate; David Wax; Clifton N Murphy; August Rieke; Kristin Whitworth; Michael L Linville; Scott W Korte; John F Engelhardt; Michael J Welsh; Randall S Prather
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.